281 related articles for article (PubMed ID: 30059414)
1. Practical Guidance on Biosimilars, With a Focus on Latin America: What Do Rheumatologists Need to Know?
Azevedo VF; Babini A; Caballero-Uribe CV; Castañeda-Hernández G; Borlenghi C; Jones HE
J Clin Rheumatol; 2019 Mar; 25(2):91-100. PubMed ID: 30059414
[TBL] [Abstract][Full Text] [Related]
2. PANLAR consensus statement on biosimilars.
Kowalski SC; Benavides JA; Roa PAB; Galarza-Maldonado C; Caballero-Uribe CV; Soriano ER; Pineda C; Azevedo VF; Avila-Pedretti G; Babini AM; Cachafeiro-Vilar A; Cifuentes-Alvarado M; Cohen SB; Díaz PE; Soto LD; Encalada C; Garro B; Sariego IAG; Guibert-Toledano M; Rodriguez VJK; Lopez MEL; Ortega AP; Russell AS; Santos-Moreno P; Terán IS; Vargas A; Vásquez G; Xavier RM; Firedman DXX; Mysler E; Kay J
Clin Rheumatol; 2019 May; 38(5):1485-1496. PubMed ID: 30915652
[TBL] [Abstract][Full Text] [Related]
3. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.
Mysler E; Pineda C; Horiuchi T; Singh E; Mahgoub E; Coindreau J; Jacobs I
Rheumatol Int; 2016 May; 36(5):613-25. PubMed ID: 26920148
[TBL] [Abstract][Full Text] [Related]
4. Biosimilars in rheumatology: understanding the rigor of their development.
Goel N; Chance K
Rheumatology (Oxford); 2017 Feb; 56(2):187-197. PubMed ID: 27241704
[TBL] [Abstract][Full Text] [Related]
5. Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries.
El Zorkany B; Al Ani N; Al Emadi S; Al Saleh J; Uthman I; El Dershaby Y; Mounir M; Al Moallim H
Clin Rheumatol; 2018 May; 37(5):1143-1152. PubMed ID: 29411181
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor necrosis factor biosimilars and intended copies in rheumatology: Perspective from the Asia Pacific region.
Rath PD; Chen DY; Gu J; Lee VWY; Al Ani NA; Shirazy K; Llamado L
Int J Rheum Dis; 2019 Jan; 22(1):9-24. PubMed ID: 30338644
[TBL] [Abstract][Full Text] [Related]
7. The changing landscape of biosimilars in rheumatology.
Dörner T; Strand V; Cornes P; Gonçalves J; Gulácsi L; Kay J; Kvien TK; Smolen J; Tanaka Y; Burmester GR
Ann Rheum Dis; 2016 Jun; 75(6):974-82. PubMed ID: 26964144
[TBL] [Abstract][Full Text] [Related]
8. Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm.
Schulze-Koops H; Skapenko A
Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv30-iv48. PubMed ID: 28903543
[TBL] [Abstract][Full Text] [Related]
9. Barriers towards effective pharmacovigilance systems of biosimilars in rheumatology: A Latin American survey.
Castañeda-Hernández G; Sandoval H; Coindreau J; Rodriguez-Davison LF; Pineda C
Pharmacoepidemiol Drug Saf; 2019 Aug; 28(8):1035-1044. PubMed ID: 31148288
[TBL] [Abstract][Full Text] [Related]
10. Era of biosimilars in rheumatology: reshaping the healthcare environment.
Smolen JS; Goncalves J; Quinn M; Benedetti F; Lee JY
RMD Open; 2019; 5(1):e000900. PubMed ID: 31245050
[TBL] [Abstract][Full Text] [Related]
11. Biosimilars in pediatric rheumatology and their introduction into routine care.
Aragon Cuevas O; Hedrich CM
Clin Immunol; 2020 Jul; 216():108447. PubMed ID: 32360950
[TBL] [Abstract][Full Text] [Related]
12. Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: innovators, biosimilars, and intended copies.
Castañeda-Hernández G; Szekanecz Z; Mysler E; Azevedo VF; Guzman R; Gutierrez M; Rodríguez W; Karateev D
Joint Bone Spine; 2014 Dec; 81(6):471-7. PubMed ID: 24956990
[TBL] [Abstract][Full Text] [Related]
13. Biosimilars in rheumatology: current perspectives and lessons learnt.
Dörner T; Kay J
Nat Rev Rheumatol; 2015 Dec; 11(12):713-24. PubMed ID: 26282080
[TBL] [Abstract][Full Text] [Related]
14. Use of Biologics and Biosimilars in Rheumatology.
Sharma SK
J Assoc Physicians India; 2017 May; 65(5 Suppl):9-14. PubMed ID: 28836745
[TBL] [Abstract][Full Text] [Related]
15. Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America.
Scheinberg M; Pineda C; Castañeda-Hernández G; Zarbá JJ; Damião A; Arantes LH; Jacobs I
MAbs; 2018; 10(6):827-842. PubMed ID: 30156950
[TBL] [Abstract][Full Text] [Related]
16. Biosimilars in psoriasis: Clinical practice and regulatory perspectives in Latin America.
de la Cruz C; de Carvalho AV; Dorantes GL; Londoño Garcia AM; Gonzalez C; Maskin M; Podoswa N; Redfern JS; Valenzuela F; van der Walt J; Romiti R
J Dermatol; 2017 Jan; 44(1):3-12. PubMed ID: 27461455
[TBL] [Abstract][Full Text] [Related]
17. Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons.
Uhlig T; Goll GL
Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv49-iv62. PubMed ID: 28903542
[TBL] [Abstract][Full Text] [Related]
18. Current state of biosimilars in Mexico: The position of the Mexican College of Rheumatology, 2016.
Xibille D; Carrillo S; Huerta-Sil G; Hernández R; Limón L; Olvera-Soto G; Jara-Quezada LJ; Esquivel A; Pérez-Rodríguez M
Reumatol Clin (Engl Ed); 2018; 14(3):127-136. PubMed ID: 28807650
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars in rheumatology.
Araújo FC; Gonçalves J; Fonseca JE
Pharmacol Res; 2019 Nov; 149():104467. PubMed ID: 31568820
[TBL] [Abstract][Full Text] [Related]
20. Biosimilars in rheumatology: perspective and concerns.
Scheinberg MA; Azevedo VF
Rheumatology (Oxford); 2014 Mar; 53(3):389-90. PubMed ID: 23878310
[No Abstract] [Full Text] [Related]
[Next] [New Search]